Individualized breast cancer therapy is based on molecular characterization [1–3], in particular the presence of receptors for estrogen (ER), progesterone (PGR) and human epidermal growth factor 2 (HER2) in an incoming patient. This evidence concerns the gene ESR1 and breast cancer.